Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs
"The upcoming presentations reflect our commitment to bring transformative therapies to patients by selectively targeting genomic drivers of disease," said
Updated clinical data will be presented in the
ASCO20 Virtual Scientific Program
Oral Presentation
Presentation Title: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors
Session Title: Drug Development for Rare Mutations: The Opportunity to Unite and Conquer
Session Date & Time (Scheduled Broadcast):
Abstract Number: 109
Poster Discussion Presentation
Presentation Title: Registrational dataset from the Phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)
Presentation Date & Time (On-Demand):
Session Title: Lung Cancer—Non-Small Cell Metastatic
Abstract Number: 9515
Poster Presentation
Presentation Title: AcceleRET Lung: A Phase III study of first-line pralsetinib in patients (pts) with RET-fusion+ advanced/metastatic non-small cell lung cancer (NSCLC)
Presentation Date & Time (On-Demand):
Session Title: Lung Cancer—Non-Small Cell Metastatic
Abstract Number: TPS9633
Late Breaking Oral Presentation
Presentation Title: Avapritinib reduced cutaneous symptoms and mast cell (MC) burden in patients (pts) with indolent systemic mastocytosis (ISM) in the PIONEER study
Presentation Date & Time (On-Demand):
Session Title: Skin Diseases: What Is New?
Abstract Number: 1832
Poster Presentations
Presentation Title: Avapritinib induces responses in patients (pts) with advanced systemic mastocytosis (AdvSM), regardless of prior midostaurin therapy
Presentation Date & Time (On-Demand):
Session Title: Myeloproliferative Neoplasms - Clinical
Abstract Number: EP1079
Presentation Title: Results from PIONEER: a randomized, double-blind, placebo-controlled, Phase 2 study of avapritinib in patients with indolent systemic mastocytosis
Presentation Date & Time (On-Demand):
Session Title: Myeloproliferative Neoplasms - Clinical
Abstract Number: EP1082
About
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have one FDA-approved precision therapy and are currently advancing multiple investigational medicines in clinical development, along with a number of research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, plans and timelines for submitting marketing applications for avapritinib and pralsetinib and, if approved, commercializing avapritinib for additional indications or pralsetinib; the potential benefits of
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-highlighting-significant-progress-in-advancing-ret-altered-cancer-and-systemic-mastocytosis-programs-301059013.html
SOURCE
Investor Relations Contact: Kristin Hodous, 617-714-6674, ir@blueprintmedicines.com. Media Relations Contact: Andrew Law, 617-844-8205, media@blueprintmedicines.com.